Clinical Features of Treatment-related Neuroendocrine Prostate Cancer: A Case Series.
Neuroendocrine differentiation
neuron-specific enolase
platinum-based chemotherapy
small-cell prostate cancer
treatment-related neuroendocrine prostate cancer
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
19
04
2020
revised:
29
04
2020
accepted:
30
04
2020
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
17
6
2020
Statut:
ppublish
Résumé
The development of treatment-related neuroendocrine prostate cancer (t-NEPC) is an increasing clinical concern. The objectives were to clarify the clinical features of t-NEPC. A total of 9 patients with histologically confirmed t-NEPC were reviewed. Of these 9 patients, 2 patients were diagnosed with t-NEPC by a histological examination without elevation in blood tumor marker levels. Immunohistochemistry revealed an acquired Rb loss in 5 patients. All patients were treated with platinum-based chemotherapy as first-line treatment and 6 patients received concurrent radiation therapy (RT). The median cancer-specific survival was 14.4 months, and 7 patients achieved an objective response. Patients with tumor-infiltrating CD8 We described the clinical features of histologically confirmed t-NEPC. In addition to the importance of biopsy, we showed that platinum-based chemotherapy plus RT had a favorable cytoreductive effect. Further clinical recognition and studies are needed.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The development of treatment-related neuroendocrine prostate cancer (t-NEPC) is an increasing clinical concern. The objectives were to clarify the clinical features of t-NEPC.
PATIENTS AND METHODS
METHODS
A total of 9 patients with histologically confirmed t-NEPC were reviewed.
RESULTS
RESULTS
Of these 9 patients, 2 patients were diagnosed with t-NEPC by a histological examination without elevation in blood tumor marker levels. Immunohistochemistry revealed an acquired Rb loss in 5 patients. All patients were treated with platinum-based chemotherapy as first-line treatment and 6 patients received concurrent radiation therapy (RT). The median cancer-specific survival was 14.4 months, and 7 patients achieved an objective response. Patients with tumor-infiltrating CD8
CONCLUSION
CONCLUSIONS
We described the clinical features of histologically confirmed t-NEPC. In addition to the importance of biopsy, we showed that platinum-based chemotherapy plus RT had a favorable cytoreductive effect. Further clinical recognition and studies are needed.
Identifiants
pubmed: 32487653
pii: 40/6/3519
doi: 10.21873/anticanres.14340
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3519-3526Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.